Silver Book Fact

Cost of pneumonia vaccine

Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.

Smith, Kenneth J., Mary Patricia Nowalk, Mahlon Raymund, and Richard K. Zimmerman. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. http://www.ncbi.nlm.nih.gov/pubmed/23806240

Reference

Title
Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults
Publication
Vaccine
Publication Date
2013
Authors
Smith, Kenneth J., Mary Patricia Nowalk, Mahlon Raymund, and Richard K. Zimmerman
Volume & Issue
Volume 31, Issue 37
Pages
3950-6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Vaccines cost ~$50 per healthy life year saved
    Most vaccinations cost less than $50 per healthy life year saved. In contrast, treating hypertension costs between $4,340 and $87,940 per healthy life year saved.  
  • Use of shingles vaccines significantly reduced disease burden
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.  
  • Over 6 years, flu vaccine prevented ~13 million cases
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…